Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Product Update

27 Jun 2007 07:01

Plant Health Care PLC27 June 2007 Embargoed until 7AM, 27 June 2007 Plant Health Care plc Myconate(R) produces outstanding yield gains in wheat. Plant Health Care (AIM: PHC.L), a leading provider of natural products forplants and soil, is pleased to report the first independent results of itsMyconate(R) testing programmes in wheat. Following impressive results in manyand varied crops over the past several years, the results of these trials nowdemonstrate the effectiveness of Myconate(R) in a new class of crops - the smallcereal grains. The Company now has compelling evidence of yield stimulation inthe two most important representatives of this class: wheat and sorghum. During the 2006/2007 season, Myconate(R) was evaluated in three separateindependent wheat trials in Mexico; two in Baja and one in Sonora. These trialswere conducted by local farmers and distributed across a wide range of soil andclimate conditions for this crop. In the Baja trials, the yield increases at the two locations were 21% and 16%;this resulted in increased income for the grower of US$385 per hectare andUS$326 per hectare respectively. In these cases the trials involved large plotsizes of 4 hectares (10 acres) so the response has been proven on growers farmsin a full commercial setting. In Sonora, the trials were established to determine the effect of seed rate andMyconate coating. In this test 20% less seed was planted in the Myconate treatedfields. The yield from both the control field and the Myconate reduced seedfields were essentially identical (approximately a 23% yield increase on theMyconate treated field when adjusted for seed rate) and the protein content ofthe Myconate(R) treated wheat was increased by 8.5%. As a result, the increasedincome to the grower for the higher yield and higher protein content would bearound US$600 per hectare. Further results of our cereal testing including more wheat, sorghum and barleytrials are expected as the year progresses. John Brady, CEO of Plant Health Care commented on the results, "Once againMyconate has proven its ability to consistently deliver improved yields in avariety of crops and under differing soil and climatic conditions. We areespecially pleased to now have large scale tests results on the important cerealgrain crops which number in excess of 300 million acres in the North America,Europe, South America and Southern Africa regions. All of this coincides withplanned timing for further Myconate supply agreements." Myconate backgroundThrough the stimulation of endogenous mycorrhizal fungi, PHC's novel Myconatetechnology helps crops to develop larger effective rooting volume. Myconateworks by triggering the germination and growth of beneficial micro-organismscalled mycorrhizal fungi which colonize the roots of crop plants. With moremycorrhizal fungi at work, each plant can draw more nutrients and moisture outof the soil. More nutrients make for healthier plants, and significantlygreater overall yields. The Board believes Myconate could be the key tochanging the face of farming. The safety and ease of application of Myconatemeans that management practices need not be over-hauled. The procedure is astraightforward blending process, either tank mixing the Myconate with thefertilizer during planting, or applying the Myconate to the seed beforeplanting. For further information please contact: Plant Heath Care plc Tavistock CommunicationsJohn Brady, Chief Executive Jeremy Carey / Simon ComptonTel: 001 603 525 3702 Tel: 020 7920 3150 Evolution Securities LimitedTim Worlledge / Tim RedfernTel: 020 7071 4312 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.